{
  "abstract": "L L mL/min/1.73m2 and hyperkalemia (-0.28 mEq/L, 95% CI -0.38 to -0.18, P<0.001) and the smallest in those with eGFR ≥45 mL/min/1.73m2 and normokalemia (-0.08 mEq/L, 95% CI -0.12 to -0.04, P<0.001; Pinteraction <0.001). Patiromer reduced time-to-first hyperkalemia consistently across subgroups. Patients with eGFR <45 mL/min/1.73m2 and baseline hyperkalemia derived the numerically greatest effect in prevention of mineralocorticoid receptor antagonist down-titration (hazard ratio 0.39, 95% CI 0.18-0.84, P=0.02) and had the highest win ratio for hyperkalemia-related morbidityadjusted outcomes (3.03, 95% CI 1.96-4.70, P<0.001). However, Pinteraction values for these secondary endpoints were not statistically significant. Conclusions: Patiromer reduced serum potassium across baseline kidney function and hyperkalemia subgroups, with greater effect in patients with reduced kidney function and baseline hyperkalemia. These findings suggest potential heterogeneity in potassium-lowering effects of patiromer across subgroups, although the analysis is exploratory and should be considered hypothesis-generating.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 25,
  "authors": [
    {
      "name": "Andreas P Kalogeropoulos"
    },
    {
      "name": "Ahmed Mustafa Rashid"
    },
    {
      "name": "Stefan D Anker"
    },
    {
      "name": "Antoni Bayes-Genis"
    },
    {
      "name": "Michael Böhm"
    },
    {
      "name": "Jeffrey Budden"
    },
    {
      "name": "John G F Cleland"
    },
    {
      "name": "Andrew J S Coats"
    },
    {
      "name": "Justin A Ezekowitz"
    },
    {
      "name": "Gerasimos Filippatos"
    },
    {
      "name": "Assen Goudev"
    },
    {
      "name": "Muhammad Shahzeb Khan"
    },
    {
      "name": "Joann Lindenfeld"
    },
    {
      "name": "Lars H Lund"
    },
    {
      "name": "Bela Merkely"
    },
    {
      "name": "Robert J Mentz"
    },
    {
      "name": "Marco Metra"
    },
    {
      "name": "Jude Moutchia"
    },
    {
      "name": "Piotr Ponikowski"
    },
    {
      "name": "Patrick Rossignol"
    },
    {
      "name": "Michele Senni"
    },
    {
      "name": "Sandra Waechter"
    },
    {
      "name": "Matthew R Weir"
    },
    {
      "name": "Bertram Pitt"
    },
    {
      "name": "Javed Butler"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/19s11k9hx6v6n.bib",
  "cited_by": 0,
  "doi": "10.34067/kid.0000001272",
  "fulltext_url": null,
  "id": "19s11k9hx6v6n",
  "issns": [
    "2641-7650",
    "2641-7650"
  ],
  "landing_url": "https://hal.univ-lorraine.fr/hal-05850584v1",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "openalex",
      "2740|Potassium and Related Disorders"
    ]
  ],
  "openalex": "W7223448770",
  "pdf_url": "https://hal.univ-lorraine.fr/hal-05850584/document",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-22",
  "publisher": "Wolters Kluwer Health Inc. on behalf of the American Society of Nephrology",
  "ris": "https://research.draconitic.com/paper/19s11k9hx6v6n.ris",
  "sources": [
    {
      "first_seen": "2026-11-05T12:20:12Z",
      "native_id": "hal-05850584",
      "source": "hal",
      "url": "https://hal.univ-lorraine.fr/hal-05850584v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:0.sdv",
      "subfield": "general"
    }
  ],
  "title": "Patiromer Efficacy across Kidney Function and Hyperkalemia Subgroups in Heart Failure and Reduced Ejection Fraction",
  "title_text": "Patiromer Efficacy across Kidney Function and Hyperkalemia Subgroups in Heart Failure and Reduced Ejection Fraction",
  "type": "peer-reviewed",
  "updated_at": "2026-11-05T12:20:12Z",
  "url": "https://research.draconitic.com/paper/19s11k9hx6v6n",
  "venue": "Kidney360",
  "versions": []
}